Announcement • Aug 07
C-MER Medical Holdings Limited to Report First Half, 2026 Results on Aug 25, 2026 C-MER Medical Holdings Limited announced that they will report first half, 2026 results on Aug 25, 2026 Upcoming Dividend • Jun 22
Upcoming dividend of HK$0.03 per share Eligible shareholders must have bought the stock before 29 June 2026. Payment date: 15 July 2026. Payout ratio is a comfortable 24% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Hong Kong dividend payers (7.3%). Lower than average of industry peers (4.9%). Declared Dividend • Mar 30
Dividend of HK$0.03 announced Shareholders will receive a dividend of HK$0.03. Ex-date: 29th June 2026 Payment date: 15th July 2026 Dividend yield will be 2.4%, which is lower than the industry average of 3.7%. Sustainability & Growth The dividend has remained flat since 7 years ago. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 73% to shift the payout ratio to a potentially unsustainable range, which is more than the 24% EPS decline seen over the last 5 years. Reported Earnings • Mar 28
Full year 2025 earnings released: EPS: HK$0.083 (vs HK$0.11 loss in FY 2024) Full year 2025 results: EPS: HK$0.083 (up from HK$0.11 loss in FY 2024). Revenue: HK$1.95b (up 1.8% from FY 2024). Net income: HK$100.4m (up HK$235.5m from FY 2024). Profit margin: 5.2% (up from net loss in FY 2024). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings. Announcement • Mar 28
C-MER Medical Holdings Limited announces Annual dividend, payable on July 15, 2026 C-MER Medical Holdings Limited announced Annual dividend of HKD 0.0200 per share payable on July 15, 2026, ex-date on June 29, 2026 and record date on June 30, 2026. Announcement • Mar 27
C-MER Medical Holdings Limited, Annual General Meeting, May 20, 2026 C-MER Medical Holdings Limited, Annual General Meeting, May 20, 2026. Buy Or Sell Opportunity • Nov 21
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 16% to HK$1.73. The fair value is estimated to be HK$2.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Oct 31
Now 21% undervalued Over the last 90 days, the stock has risen 1.7% to HK$1.82. The fair value is estimated to be HK$2.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Sep 27
First half 2025 earnings released: EPS: HK$0.041 (vs HK$0.025 in 1H 2024) First half 2025 results: EPS: HK$0.041 (up from HK$0.025 in 1H 2024). Revenue: HK$944.3m (up 2.4% from 1H 2024). Net income: HK$49.9m (up 62% from 1H 2024). Profit margin: 5.3% (up from 3.3% in 1H 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 27
First half 2025 earnings released: EPS: HK$0.041 (vs HK$0.025 in 1H 2024) First half 2025 results: EPS: HK$0.041 (up from HK$0.025 in 1H 2024). Revenue: HK$944.3m (up 2.4% from 1H 2024). Net income: HK$49.9m (up 62% from 1H 2024). Profit margin: 5.3% (up from 3.3% in 1H 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance. Announcement • Aug 11
C-MER Medical Holdings Limited to Report First Half, 2025 Results on Aug 26, 2025 C-MER Medical Holdings Limited announced that they will report first half, 2025 results on Aug 26, 2025 Upcoming Dividend • Jun 20
Upcoming dividend of HK$0.02 per share Eligible shareholders must have bought the stock before 27 June 2025. Payment date: 15 July 2025. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.1%. Lower than top quartile of Hong Kong dividend payers (7.5%). Lower than average of industry peers (4.1%). Announcement • May 20
C-Mer Medical Holdings Limited Approves Final Dividend for the Year Ended 31 December 2024 C-MER Medical Holdings Limited at its AGM held on 19 May 2025 approved to declare a final dividend of HK 2.0 cents per Share for the year ended 31 December 2024. Buy Or Sell Opportunity • Apr 28
Now 20% overvalued Over the last 90 days, the stock has fallen 15% to HK$1.65. The fair value is estimated to be HK$1.37, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Apr 24
Full year 2024 earnings released: HK$0.11 loss per share (vs HK$0.049 profit in FY 2023) Full year 2024 results: HK$0.11 loss per share (down from HK$0.049 profit in FY 2023). Revenue: HK$1.91b (flat on FY 2023). Net loss: HK$135.2m (down 318% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year whereas the company’s share price has fallen by 28% per year. New Risk • Mar 22
New major risk - Revenue and earnings growth Earnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Announcement • Mar 03
C-MER Medical Holdings Limited to Report Fiscal Year 2024 Results on Mar 21, 2025 C-MER Medical Holdings Limited announced that they will report fiscal year 2024 results on Mar 21, 2025 Valuation Update With 7 Day Price Move • Oct 01
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to HK$2.81, the stock trades at a trailing P/E ratio of 54.8x. Average forward P/E is 12x in the Healthcare industry in Hong Kong. Total loss to shareholders of 65% over the past three years. Recent Insider Transactions • Sep 17
Chairman & CEO recently bought HK$776k worth of stock On the 16th of September, Shun Chiu Lam bought around 380k shares on-market at roughly HK$2.04 per share. This transaction amounted to 3.4% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth HK$920k. Shun Chiu has been a buyer over the last 12 months, purchasing a net total of HK$6.0m worth in shares. Valuation Update With 7 Day Price Move • Sep 05
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to HK$1.86, the stock trades at a trailing P/E ratio of 36.7x. Average forward P/E is 7x in the Healthcare industry in Hong Kong. Total loss to shareholders of 77% over the past three years. Reported Earnings • Aug 31
First half 2024 earnings released: EPS: HK$0.025 (vs HK$0.024 in 1H 2023) First half 2024 results: EPS: HK$0.025 (up from HK$0.024 in 1H 2023). Revenue: HK$922.5m (down 2.9% from 1H 2023). Net income: HK$30.8m (up 3.4% from 1H 2023). Profit margin: 3.3% (up from 3.1% in 1H 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Announcement • Aug 15
C-MER Medical Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024 C-MER Medical Holdings Limited announced that they will report first half, 2024 results on Aug 29, 2024 Recent Insider Transactions • Jul 21
Chairman & CEO recently bought HK$841k worth of stock On the 17th of July, Shun Chiu Lam bought around 320k shares on-market at roughly HK$2.63 per share. This transaction amounted to 3.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Shun Chiu has been a buyer over the last 12 months, purchasing a net total of HK$2.5m worth in shares. Announcement • Mar 28
C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024 C-MER Eye Care Holdings Limited, Annual General Meeting, May 28, 2024. New Risk • Mar 27
New major risk - Revenue and earnings growth Earnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Announcement • Mar 09
C-MER Eye Care Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 C-MER Eye Care Holdings Limited announced that they will report fiscal year 2023 results on Mar 26, 2024 Price Target Changed • Sep 02
Price target decreased by 12% to HK$4.50 Down from HK$5.10, the current price target is provided by 1 analyst. New target price is 22% above last closing price of HK$3.69. Stock is down 7.3% over the past year. The company posted a net loss per share of HK$0.018 last year. Reported Earnings • Sep 01
First half 2023 earnings released: EPS: HK$0.024 (vs HK$0.012 in 1H 2022) First half 2023 results: EPS: HK$0.024 (up from HK$0.012 in 1H 2022). Revenue: HK$950.3m (up 7.8% from 1H 2022). Net income: HK$29.8m (up 101% from 1H 2022). Profit margin: 3.1% (up from 1.7% in 1H 2022). Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Announcement • Aug 18
C-MER Eye Care Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023 C-MER Eye Care Holdings Limited provided earnings guidance for the six months ended 30 June 2023. For the period, profit attributable to shareholders of the Company for the six months ended 30 June 2023 ("1H2023") is expected to be in the range of HKD 25.0 million to HKD 30.0 million, or an increase of around 68% to 102%, as compared with profits of HKD 14.8 million for the same period last year. The expected increase in profit attributable to shareholders of the Company was primarily driven by an over 40% increase in revenue generated from medical service to approximately HKD 930.0 million in 1H2023 from HKD 660.8 million for the same period last year, partially net off by the reduction in revenue generated from sale of COVID-19 related medical consumables to approximately HKD 19.0 million in 1H2023 from HKD 220.7 million for the same period last year. Announcement • Aug 11
C-MER Eye Care Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023 C-MER Eye Care Holdings Limited announced that they will report first half, 2023 results on Aug 30, 2023 Announcement • Jun 29
C-MER Eye Care Holdings Limited Announces Board Changes, Effective July 3, 2023 The board of directors of C-MER Eye Care Holdings Limited announced that Mr. Yin Ke ("Mr. YIN") has been appointed as an independent non-executive director of the Company with effect from 3 July 2023. Mr. YIN, aged 59, graduated with a bachelor's degree in electrical engineering and a master's degree in economics from Zhejiang University, the PRC. Mr. YIN previously worked as a Secretary to the President of the Shenzhen Stock Exchange. He also served as the Deputy General Manager and an Executive Director of Jun'an Securities Co. Ltd., a Board Director of Guotai Junan Securities Co. Ltd., the President and an Executive Director of China United Securities Co. Ltd., a Director and the Deputy Chief Executive Officer of CITIC Capital Holdings Limited, a Non- executive Director of CITIC Dameng Holdings Limited, an Independent Director of CCB Principal Asset Management Co. Ltd., the Chief Executive Officer of CITIC Securities International Limited and an Executive Director and the Vice Chairman of CITIC Pacific Limited. In addition, Mr. YIN served as the Vice Chairman of CITIC Securities Company Limited from 2011 to 2016 and its Executive Director from 2009 to 2017, and a Non-executive Director of CITIC Limited from 2009 to 2014, both of which are listed on The Stock Exchange of Hong Kong Limited. He was also a Non-executive Director of Dah Chong Hong Holdings Limited from 2010 to 2012 and from 2018 to 2020, which was delisted from the Stock Exchange in 2020. He was a non-executive director of Hui Xian Asset Management Limited from October 2011 to January 2018. Mr. YIN was a member of the Financial Service Committee of Hong Kong Trade Development Council from 2017 to 2022. Mr. YIN currently serves as an External Director of Shandong Heavy Industry Group Co. Ltd. and an Independent Non-executive Director of Hui Xian Real Estate Investment Trust (stock code: 87001), which is listed on the Stock Exchange, an Independent Non- executive Director of Focus Media Information Technology Co. Ltd., which is listed on the Shenzhen Stock Exchange. Mr. YIN also serves as a Senior Advisor to CPP Investments. He is a director of Beijing Oriental Plaza Co. Ltd. The Board announces that Mr. LI Chunshan has notified the Board that he will step down as an executive director of the Company with effect from 3 July 2023 as he is close to retirement age. Mr. LI will however continue to serve the Group in his capacity as a director of certain of its subsidiaries in the PRC. Mr. YIN has been appointed as a member of each of the Audit Committee and the Nomination Committee of the Company with effect from 3 July 2023. Concurrent with Mr. YIN's appointments to these committees, Dr. Rex AUYEUNG Pak-kuen will step down as a member of the Audit Committee, and Ms. LI Xiaoting will also step down as a member of the Nomination Committee on the same date. Board Change • May 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. Independent Non-Executive Director Andrew Ma was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Buying Opportunity • May 09
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be HK$5.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last 3 years. Meanwhile, the company became loss making. Buying Opportunity • Apr 25
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be HK$5.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Apr 01
Full year 2022 earnings released: HK$0.018 loss per share (vs HK$0.019 profit in FY 2021) Full year 2022 results: HK$0.018 loss per share (down from HK$0.019 profit in FY 2021). Revenue: HK$1.73b (up 56% from FY 2021). Net loss: HK$21.9m (down 200% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Buying Opportunity • Feb 03
Now 22% undervalued Over the last 90 days, the stock is up 46%. The fair value is estimated to be HK$6.59, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 37% over the last 3 years. Earnings per share has declined by 35%. Revenue is forecast to grow by 24% in a year. Earnings is forecast to grow by 393% in the next year. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. Independent Non-Executive Director Andrew Ma was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Recent Insider Transactions • Nov 02
Chairman & CEO recently bought HK$1.9m worth of stock On the 28th of October, Shun Chiu Lam bought around 608k shares on-market at roughly HK$3.18 per share. This transaction amounted to 8.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Shun Chiu has been a buyer over the last 12 months, purchasing a net total of HK$20m worth in shares. Recent Insider Transactions • Oct 02
Chairman & CEO recently bought HK$1.3m worth of stock On the 29th of September, Shun Chiu Lam bought around 380k shares on-market at roughly HK$3.37 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Shun Chiu has been a buyer over the last 12 months, purchasing a net total of HK$3.7m worth in shares. Board Change • Sep 26
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. Independent Non-Executive Director Andrew Ma was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Sep 01
First half 2022 earnings released: EPS: HK$0.012 (vs HK$0.012 in 1H 2021) First half 2022 results: EPS: HK$0.012 (vs HK$0.012 in 1H 2021). Revenue: HK$881.6m (up 69% from 1H 2021). Net income: HK$14.8m (up 8.0% from 1H 2021). Profit margin: 1.7% (down from 2.6% in 1H 2021). Over the next year, revenue is forecast to grow 24%, compared to a 33% growth forecast for the Healthcare industry in Hong Kong. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Board Change • Aug 26
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. Independent Non-Executive Director Johnson Lau was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 30
Full year 2021 earnings released: EPS: HK$0.019 (vs HK$0.006 loss in FY 2020) Full year 2021 results: EPS: HK$0.019 (up from HK$0.006 loss in FY 2020). Revenue: HK$1.11b (up 59% from FY 2020). Net income: HK$21.9m (up HK$28.1m from FY 2020). Profit margin: 2.0% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Recent Insider Transactions Derivative • Dec 11
Executive Director exercised options to buy HK$1.7m worth of stock. On the 8th of December, Yau Wing Lee exercised options to buy 250k shares at a strike price of around HK$5.18, costing a total of HK$1.3m. This transaction amounted to 1.9% of their direct individual holding at the time of the trade. Since December 2020, Yau Wing's direct individual holding has decreased from 12.95m shares to . Company insiders have collectively bought HK$2.9m more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Sep 03
First half 2021 earnings released: EPS HK$0.012 (vs HK$0.02 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: HK$521.4m (up 99% from 1H 2020). Net income: HK$13.7m (up HK$34.7m from 1H 2020). Profit margin: 2.6% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings. Recent Insider Transactions • Jun 09
Independent Non-Executive Director recently bought HK$1.6m worth of stock On the 8th of June, Chi Leong Chan bought around 250k shares on-market at roughly HK$6.50 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought HK$6.4m more in shares than they have sold in the last 12 months. Upcoming Dividend • May 24
Upcoming dividend of HK$0.02 per share Eligible shareholders must have bought the stock before 31 May 2021. Payment date: 28 June 2021. Trailing yield: 0.3%. Lower than top quartile of Hong Kong dividend payers (6.0%). Lower than average of industry peers (2.3%). Reported Earnings • Apr 24
Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019) The company reported a soft full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: HK$699.5m (up 21% from FY 2019). Net loss: HK$6.25m (down 115% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 01
Full year 2020 earnings released: HK$0.006 loss per share (vs HK$0.04 profit in FY 2019) The company reported a soft full year result with weaker earnings and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: HK$699.5m (up 21% from FY 2019). Net loss: HK$6.25m (down 115% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 18
New 90-day high: HK$6.89 The company is up 14% from its price of HK$6.04 on 20 November 2020. The Hong Kong market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 19% over the same period. Is New 90 Day High Low • Jan 25
New 90-day high: HK$6.44 The company is up 15% from its price of HK$5.58 on 27 October 2020. The Hong Kong market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 27% over the same period. Recent Insider Transactions • Nov 11
Independent Non-Executive Director recently bought HK$1.8m worth of stock On the 6th of November, Pak-kuen Auyeung bought around 300k shares on-market at roughly HK$6.05 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought HK$5.8m more in shares than they have sold in the last 12 months. Is New 90 Day High Low • Oct 27
New 90-day low: HK$5.58 The company is down 17% from its price of HK$6.73 on 29 July 2020. The Hong Kong market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 2.0% over the same period. Recent Insider Transactions • Oct 20
Independent Non-Executive Director recently bought HK$208k worth of stock On the 16th of October, Chi Leong Chan bought around 36k shares on-market at roughly HK$5.78 per share. In the last 3 months, they made an even bigger purchase worth HK$501k. Insiders have collectively bought HK$11m more in shares than they have sold in the last 12 months. Is New 90 Day High Low • Sep 25
New 90-day low: HK$5.86 The company is down 5.0% from its price of HK$6.19 on 26 June 2020. The Hong Kong market is down 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 7.0% over the same period. Reported Earnings • Sep 24
First half earnings released Over the last 12 months the company has reported total losses of HK$13.3m, with earnings decreasing by HK$77.5m from the prior year. Total revenue was HK$573.4m over the last 12 months, up 14% from the prior year. Recent Insider Transactions • Sep 23
Independent Non-Executive Director recently bought HK$138k worth of stock On the 22nd of September, Chi Leong Chan bought around 22k shares on-market at roughly HK$6.26 per share. In the last 3 months, they made an even bigger purchase worth HK$501k. Insiders have collectively bought HK$10m more in shares than they have sold in the last 12 months. 
